Rockwell Medical Inc. has released its financial results for the second quarter of 2025. The company confirmed its annual guidance for 2025, forecasting net sales between $65 million and $70 million, with a gross margin ranging from 16% to 18%. The adjusted EBITDA is expected to be between a loss of $0.5 million and a gain of $0.5 million. Over 80% of Rockwell Medical's customers are currently under long-term contracts. Additionally, the company continues to hold its place on the Russell Microcap® Index for the third consecutive year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rockwell Medical Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814582605) on August 14, 2025, and is solely responsible for the information contained therein.